Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
ApexOnco Front Page
Recent articles
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
The company will imminently start its third pivotal trial of PF-08634404.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The company ditches lorigerlimab in prostate cancer.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
